Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S of Innovent Biologics, Inc. The net proceeds from the offering amounted to approximately HK$3.155 billion (US$403.1 million) prior to the exercise of the over-allotment option.

Innovent Biologics, Inc. is a China-based biopharmaceutical company that develops and commercializes high quality drugs. Founded by Dr. De-Chao Michael Yu in 2011, Innovent Biologics, Inc. has built up a pipeline of 17 antibody drug candidates, with four core products in late-stage clinical development in China.

The Davis Polk corporate team included partners Paul Chow and Li He, counsel Yang Chu and registered foreign lawyers Xuelin (Steve) Wang and Andrea Feuer. All members of the Davis Polk team are based in the Hong Kong office.

Copy link to share post